Non-invasive brain stimulation techniques for chronic pain

  • Review
  • Intervention


  • Neil E O'Connell,

    Corresponding author
    1. Brunel University, Department of Clinical Sciences/Health Economics Research Group, Institute of Environment, Health and Societies, Uxbridge, Middlesex, UK
    • Neil E O'Connell, Department of Clinical Sciences/Health Economics Research Group, Institute of Environment, Health and Societies, Brunel University, Kingston Lane, Uxbridge, Middlesex, UB8 3PH, UK.

  • Louise Marston,

    1. University College London, Research Department of Primary Care & Population Health, London, UK
  • Sally Spencer,

    1. Edge Hill University, Postgraduate Medical Institute, Ormskirk, Lancashire, UK
  • Lorraine H DeSouza,

    1. Brunel University London, Department of Clinical Sciences/Health Ageing Research Group, Institute of Environment, Health and Societies, Uxbridge, Middlesex, UK
  • Benedict M Wand

    1. The University of Notre Dame Australia, School of Physiotherapy, Fremantle, West Australia, Australia



This is an updated version of the original Cochrane Review published in 2010, Issue 9, and last updated in 2014, Issue 4. Non-invasive brain stimulation techniques aim to induce an electrical stimulation of the brain in an attempt to reduce chronic pain by directly altering brain activity. They include repetitive transcranial magnetic stimulation (rTMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), transcranial random noise stimulation (tRNS) and reduced impedance non-invasive cortical electrostimulation (RINCE).


To evaluate the efficacy of non-invasive cortical stimulation techniques in the treatment of chronic pain.

Search methods

For this update we searched CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, LILACS and clinical trials registers from July 2013 to October 2017.

Selection criteria

Randomised and quasi-randomised studies of rTMS, CES, tDCS, RINCE and tRNS if they employed a sham stimulation control group, recruited patients over the age of 18 years with pain of three months' duration or more, and measured pain as an outcome. Outcomes of interest were pain intensity measured using visual analogue scales or numerical rating scales, disability, quality of life and adverse events.

Data collection and analysis

Two review authors independently extracted and verified data. Where possible we entered data into meta-analyses, excluding studies judged as high risk of bias. We used the GRADE system to assess the quality of evidence for core comparisons, and created three 'Summary of findings' tables.

Main results

We included an additional 38 trials (involving 1225 randomised participants) in this update, making a total of 94 trials in the review (involving 2983 randomised participants). This update included a total of 42 rTMS studies, 11 CES, 36 tDCS, two RINCE and two tRNS. One study evaluated both rTMS and tDCS. We judged only four studies as low risk of bias across all key criteria. Using the GRADE criteria we judged the quality of evidence for each outcome, and for all comparisons as low or very low; in large part this was due to issues of blinding and of precision.


Meta-analysis of rTMS studies versus sham for pain intensity at short-term follow-up (0 to < 1 week postintervention), (27 studies, involving 655 participants), demonstrated a small effect with heterogeneity (standardised mean difference (SMD) -0.22, 95% confidence interval (CI) -0.29 to -0.16, low-quality evidence). This equates to a 7% (95% CI 5% to 9%) reduction in pain, or a 0.40 (95% CI 0.53 to 0.32) point reduction on a 0 to 10 pain intensity scale, which does not meet the minimum clinically important difference threshold of 15% or greater. Pre-specified subgroup analyses did not find a difference between low-frequency stimulation (low-quality evidence) and rTMS applied to the prefrontal cortex compared to sham for reducing pain intensity at short-term follow-up (very low-quality evidence). High-frequency stimulation of the motor cortex in single-dose studies was associated with a small short-term reduction in pain intensity at short-term follow-up (low-quality evidence, pooled n = 249, SMD -0.38 95% CI -0.49 to -0.27). This equates to a 12% (95% CI 9% to 16%) reduction in pain, or a 0.77 (95% CI 0.55 to 0.99) point change on a 0 to 10 pain intensity scale, which does not achieve the minimum clinically important difference threshold of 15% or greater. The results from multiple-dose studies were heterogeneous and there was no evidence of an effect in this subgroup (very low-quality evidence). We did not find evidence that rTMS improved disability. Meta-analysis of studies of rTMS versus sham for quality of life (measured using the Fibromyalgia Impact Questionnaire (FIQ) at short-term follow-up demonstrated a positive effect (MD -10.80 95% CI -15.04 to -6.55, low-quality evidence).


For CES (five studies, 270 participants) we found no evidence of a difference between active stimulation and sham (SMD -0.24, 95% CI -0.48 to 0.01, low-quality evidence) for pain intensity. We found no evidence relating to the effectiveness of CES on disability. One study (36 participants) of CES versus sham for quality of life (measured using the FIQ) at short-term follow-up demonstrated a positive effect (MD -25.05 95% CI -37.82 to -12.28, very low-quality evidence).


Analysis of tDCS studies (27 studies, 747 participants) showed heterogeneity and a difference between active and sham stimulation (SMD -0.43 95% CI -0.63 to -0.22, very low-quality evidence) for pain intensity. This equates to a reduction of 0.82 (95% CI 0.42 to 1.2) points, or a percentage change of 17% (95% CI 9% to 25%) of the control group outcome. This point estimate meets our threshold for a minimum clinically important difference, though the lower confidence interval is substantially below that threshold. We found evidence of small study bias in the tDCS analyses. We did not find evidence that tDCS improved disability. Meta-analysis of studies of tDCS versus sham for quality of life (measured using different scales across studies) at short-term follow-up demonstrated a positive effect (SMD 0.66 95% CI 0.21 to 1.11, low-quality evidence).

Adverse events

All forms of non-invasive brain stimulation and sham stimulation appear to be frequently associated with minor or transient side effects and there were two reported incidences of seizure, both related to the active rTMS intervention in the included studies. However many studies did not adequately report adverse events.

Authors' conclusions

There is very low-quality evidence that single doses of high-frequency rTMS of the motor cortex and tDCS may have short-term effects on chronic pain and quality of life but multiple sources of bias exist that may have influenced the observed effects. We did not find evidence that low-frequency rTMS, rTMS applied to the dorsolateral prefrontal cortex and CES are effective for reducing pain intensity in chronic pain. The broad conclusions of this review have not changed substantially for this update. There remains a need for substantially larger, rigorously designed studies, particularly of longer courses of stimulation. Future evidence may substantially impact upon the presented results.

Plain language summary

Stimulating the brain without surgery in the management of chronic pain in adults

Bottom line

There is a lack of high-quality evidence to support or refute the effectiveness of non-invasive brain stimulation techniques for chronic pain.


Electrical stimulation of the brain has been used to address a variety of painful conditions. Various devices are available that can electrically stimulate the brain without the need for surgery or any invasive treatment. There are five main treatment types: repetitive transcranial magnetic stimulation (rTMS) in which the brain is stimulated by a coil applied to the scalp, cranial electrotherapy stimulation (CES) in which electrodes are clipped to the ears or applied to the scalp, transcranial direct current stimulation (tDCS), reduced impedance non-invasive cortical electrostimulation (RINCE) and transcranial random noise stimulation (tRNS) in which electrodes are applied to the scalp. These have been used to try to reduce pain by aiming to alter the activity of the brain. How effective they are is uncertain.

Study characteristics

This review update included 94 randomised controlled studies: 42 of rTMS, 11 of CES, 36 of tDCS two of RINCE, two of tRNS and one study which evaluated both tDCS and rTMS.

Key findings

rTMS applied to the motor cortex may lead to small, short-term reductions in pain but these effects are not likely to be clinically important. tDCS may reduce pain when compared with sham but for rTMS and tDCS our estimates of benefit are likely to be exaggerated by the small number of participants in each of the studies and limitations in the way the studies were conducted. Low- or very low-quality evidence suggests that low-frequency rTMS and rTMS that is applied to prefrontal areas of the brain are not effective. Low-quality evidence does not suggest that CES is an effective treatment for chronic pain. For all forms of stimulation the evidence is not conclusive and there is substantial uncertainty about the possible benefits and harms of the treatment. Of the studies that clearly reported side effects, short-lived and minor side effects such as headache, nausea and skin irritation were usually reported both with real and sham stimulation. Two cases of seizure were reported following real rTMS. Our conclusions for rTMS, CES, tDCS, and RINCE have not changed substantially in this update.

Quality of the evidence

We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means that we are very uncertain about the results. High-quality evidence means that we are very confident in the results. We considered all of the evidence to be of low or very low quality, mainly because of bias in the studies that can lead to unreliable results and the small size of the studies, which makes them imprecise.

Laički sažetak

Metode stimulacije mozga bez kirurškog zahvata za liječenje kronične boli


Nemamo dovoljno visoko-kvalitetnih dokaza koji bi podržali ili osporili učinkovitost metoda za neinvazivnu stimulaciju mozga za liječenje kronične boli.

Dosadašnje spoznaje

Električna stimulacija mozga se koristi za liječenje raznih bolnih stanja. Danas postoje različiti uređaji koji omogućuju električnu stimulaciju mozga bez potrebe za kirurškim zahvatom ili bilo kakvom drugom invazivnom terapijom. Postoji pet glavnih vrste tih terapija: ponavljana transkranijalna magnetska stimulacija (engl. repetitive transcranial magnetic stimulation, rTMS) kod koje se mozak stimulira pomoću zavojnice koja se stavlja na kožu glave, kranijalna elektroterapijska stimulacija (engl. cranial electrotherapy stimulation, CES) kod koje se elektrode zakače na uši ili stavljaju na kožu glave; transkranijalna direktna stimulacija strujom (engl. transcranial direct current stimulation, tDCS), neinvazinva kortikalna elektrostimulacija smanjene impedancije (engl. reduced impedance non-invasive cortical electrostimulation, RINCE) i transkranijalna nasumična stimulacija bukom (engl. transcranial random noise stimulation, tRNS) kod koje se elektrode primjenjuju na kožu glave. Ti se uređaji pokušavaju koristiti za ublažavanje boli, pri čemu im je cilj mijenjanje aktivnosti mozga. Međutim, nije jasno kolika je djelotvornost tih terapija.

Obilježja uključenih istraživanja

U ovoj obnovljenoj verziji Cochrane sustavnog pregleda literature uključena su 94 randomizirana kontrolirana istraživanja. Od toga su 42 pokusa analizirala rTMS, 11 CES, 36 tDCS, 2 RINCE, 2 tRNS, a jedan pokus je ispitao i tDCS i rTMS.

Ključni rezultati

Kad se rTMS primijeni na motornu koru mozga (korteks) može dovesti do malog, kratkoročnog smanjenja boli, ali nije vjerojatno da su ti učinci klinički važna. tDCS može smanjiti bol u usporedbi s placebo postupkom, ali za rTMS i tDCS naše procjene pokazuju da je njihov koristan učinak vjerojatno precijenjen zbog malog broja sudionika u svakoj od studija i ograničenja u načinu na koji su ta istraživanja provedena. Dokazi niske- ili vrlo niske kvalitete ukazuju kako rTMS i rTMS niske frekvencije, koje se primjenjuju na prefrontalna područja mozga, nisu učinkovite. Dokazi niske kvalitete pokazuju da CES nije djelotvorna terapija za kroničnu bol. Za sve oblike stimulacije dokazi nisu uvjerljivi i postoji znatna neizvjesnost oko moguće koristi i štetnih učinaka tih terapija. U studijama koje su jasno opisale nuspojave, te su nuspojave bile kratkoročne i sporedne, primjerice glavobolja, mučnina i nadražaj kože, ali takve su nuspojave ispitanici opisali i prilikom stvarne i lažne stimulacije. Dva slučaja napadaja su opisana nakon primjene prave rTMS. Naši zaključci za rTMS, CES, tDCS i RINCE nisu se značajnije promijenili u ovom obnovljenom sustavnom pregledu u odnosu na stariju verziju.

Kvaliteta dokaza

Ocijenjenili smo kvalitetu dokaza iz uključenih istraživanja s pomoću četiri razine: vrlo niske, niske, umjerene ili visoke Vrlo niska kvaliteta dokaza znači da smo jako nesigurni oko rezultata. Visoka kvaliteta dokaza znači da smo vrlo sigurni u rezultate. Ocijenili smo da su svi dokazi u ovom sustavnom pregledu niske ili vrlo niske kvalitete, uglavnom zbog pristranosti koje mogu dovesti do nepouzdanih rezultata i male veličine studija, što ih čini neprecizan.

Bilješke prijevoda

Hrvatski Cochrane
Prevela: Livia PuljakOvaj sažetak preveden je u okviru volonterskog projekta prevođenja Cochrane sažetaka. Uključite se u projekt i pomozite nam u prevođenju brojnih preostalih Cochrane sažetaka koji su još uvijek dostupni samo na engleskom jeziku. Kontakt:

Ringkasan bahasa mudah

Merangsang otak tanpa pembedahan dalam pengurusan sakit kronik dalam kalangan orang dewasa


Terdapat kekurangan bukti berkualiti tinggi untuk menyokong atau menafikan keberkesanan teknik rangsangan otak tidak invasif untuk sakit kronik.

Latar belakang

Rangsangan elektrik otak telah digunakan untuk menangani pelbagai keadaan yang menyakitkan. Terdapat pelbagai peranti yang boleh merangsang otak secara elektrik tanpa memerlukan pembedahan atau rawatan invasif. Terdapat lima jenis rawatan utama: rangsangan magnetik transkranial berulang (rTMS) di mana otak dirangsang oleh gegelung yang diaplikasi pada kulit kepala, rangsangan elektroterapi kranial (CES) di mana elektrod diletakkan ke telinga atau diaplikasi pada kulit kepala, rangsangan transkranial arus terus (tDCS), elektrostimulasi kortikal terkurang impedans yang tidak invasif (RINCE) dan rangsangan bunyi transkranial rawak (tRNS) di mana elektrod diaplikasi pada kulit kepala. Rawatan tersebut telah digunakan untuk mengurangkan sakit dengan matlamat mengubah aktiviti otak. Keberkesanannya adalah tidak pasti.

Ciri-ciri kajian

Kemas kini ulasan ini termasuk 94 kajian rawak terkawal: 42 rTMS, 11 CES, 36 tDCS, dua RINCE, dua tRNS dan satu kajian yang menilai kedua-dua tDCS dan rTMS.

Keputusan utama

rTMS yang diaplikasi kepada korteks motor boleh membawa kepada pengurangan kecil jangka pendek sakit tetapi kesannya tidak mungkin penting secara klinikal. tDCS boleh mengurangkan sakit berbanding dengan sham tetapi untuk rTMS dan tDCS anggaran manfaat kami mungkin diperbesar-besarkan oleh bilangan peserta yang kecil dalam setiap kajian dan batasan dalam cara kajian dijalankan. Bukti kualiti rendah atau sangat rendah menunjukkan frekuensi rendah rTMS dan rTMS yang diaplikasi pada kawasan prefrontal otak tidak berkesan. Bukti berkualiti rendah tidak menunjukkan CES adalah rawatan yang berkesan untuk sakit kronik. Untuk semua bentuk rangsangan, bukti adalah tidak konklusif dan terdapat ketidakpastian besar mengenai kemungkinan manfaat dan bahaya rawatan. Antara kajian yang melaporkan dengan jelas kesan sampingan, kesan sampingan yang singkat dan kecil seperti sakit kepala, loya dan kerengsaan kulit biasanya dilaporkan dengan rangsangan sebenar dan palsu. Dua kes sawan dilaporkan berikutan rTMS sebenar. Kesimpulan kami untuk rTMS, CES, tDCS, dan RINCE tidak berubah dengan ketara dalam kemas kini ini.

Kualiti bukti

Kami menilai kualiti bukti dari kajian-kajian menggunakan empat peringkat: sangat rendah, rendah, sederhana, atau tinggi. Bukti yang berkualiti sangat rendah bermakna kami sangat tidak pasti tentang hasilnya. Bukti yang berkualiti tinggi bermakna kami sangat yakin dengan hasilnya. Kami menganggap semua bukti mempunyai kualiti rendah atau sangat rendah, terutamanya kerana bias dalam kajian-kajian tersebut yang boleh membawa kepada hasil yang tidak boleh dipercayai dan saiz kecil kajian, yang menjadikannya tidak tepat.

Catatan terjemahan

Diterjemahkan oleh Wong Chun Hoong (International Medical University). Disunting oleh Noorliza Mastura Ismail (Kolej Perubatan Melaka-Manipal). Untuk sebarang pertanyaan berkaitan terjemahan ini sila hubungi

Laienverständliche Zusammenfassung

Stimulation des Gehirns ohne Operation zur Behandlung von chronischen Schmerzen bei Erwachsenen


Es fehlt an Evidenz von hoher Qualität, die die Wirksamkeit von nicht-invasiven Hirnstimulationsverfahren bei chronischen Schmerzen belegt bzw. widerlegt.


Elektrische Hirnstimulation wird zur Behandlung verschiedener schmerzhafter Erkrankungen eingesetzt. Verschiedene Geräte für eine elektrische Hirnstimulation stehen zur Verfügung, die keine Operation bzw. invasiven Eingriff erfordern. Es gibt fünf hauptsächliche Behandlungsarten: repetitive transkranielle Magnetstimulation (rTMS), bei der das Hirn mittels einer an der Kopfhaut angelegten Magnetspule stimuliert wird; craniale Elektrostimulation (CES), bei der Elektroden an den Ohren oder der Kopfhaut angelegt werden; transkranielle Gleichstromstimulation (tDCS); nicht-invasive kortikale Elektrostimulation mit reduzierter Impedanz (RINCE) und transkranielle Rauschstromstimulation (tRNS), bei der die Elektroden an der Kopfhaut angelegt werden. Diese Behandlungsmethoden werden genutzt um zu versuchen, eine Schmerzreduktion über veränderte Hirnaktivität zu erreichen. Ihre Wirksamkeit ist unklar.


Diese Aktualisierung eines Reviews schließt 94 randomisierte kontrollierte Studien ein: 42 rTMS-Studien, 11 CES-Studien, 36 tDCS-Studien, 2 RINCE-Studien, 2 tRNS-Studien und eine Studie, die tDCS und rTMS untersuchte.


rTMS, angewendet auf den Motorcortex, führt möglicherweise zu leichter, kurzzeitiger Schmerzreduktion, allerdings sind diese Wirkungen wahrscheinlich nicht klinisch relevant. tDCS reduziert im Vergleich zur scheinbehandelten Gruppe möglicherweise Schmerzen, allerdings sind unsere Schätzungen für den Nutzen von rTMS und tDCS durch die geringe Teilnehmeranzahl in jeder der Studien und den Einschränkungen in der Studiendurchführung wahrscheinlich überhöht. Es liegt Evidenz von niedriger bzw. sehr niedriger Qualität vor, die nahelegt, dass niederfrequente rTMS bzw. rTMS, die auf präfrontale Hirnareale angewendet wird, nicht wirksam sind. Evidenz von niedriger Qualität spricht nicht dafür, dass CES eine wirksame Behandlung für chronische Schmerzen darstellt. Für alle Formen der Stimulation ist die Evidenzlage nicht eindeutig, und es besteht erhebliche Unsicherheit hinsichtlich des möglichen Nutzens bzw. Schadens der Behandlung. Von den Studien, die ausdrücklich über Nebenwirkungen berichteten, wurden kurzzeitige und geringfügige Nebenwirkungen wie Kopfschmerzen, Übelkeit und Hautirritationen sowohl bei den wirklichen, als auch bei den Scheinstimulationen häufig berichtet. Zwei Fälle von Anfällen nach rTMS-Anwendungen wurden berichtet. Unsere Schlussfolgerungen bezüglich rTMS, CES, tDCS und RINCE haben sich mit dieser Aktualisierung nicht erheblich geändert.

Qualität der Evidenz

Wir bewerten die Qualität der Studien anhand von vierAbstufungen: sehr niedrig, niedrig, moderat oder hoch. Evidenz von sehr niedriger Qualität bedeutet, dass wir hinsichtlich der Ergebnisse sehr unsicher sind. Evidenz von hoher Qualität bedeutet, dass wir großes Vertrauen in die Ergebnissen haben. Wir bewerteten die Qualität der gesamten Evidenz als niedrig bzw. sehr niedrig, hauptsächlich aufgrund von Bias in den Studien, was zu nicht verlässlichen Ergebnissen führen kann, und aufgrund der geringen Größe der Studien, die die Studien unpräzise werden lässt.

Anmerkungen zur Übersetzung

C. Wetzel, freigegeben durch Cochrane Deutschland.